Could Drug Price Spikes Spur ANDA Priority Reviews?
This article was originally published in The Pink Sheet Daily
Sens. Collins and Warren want FDA to have economic trigger to speed generics; CDER's Woodcock says it's possible but needs clear legislative definition.
Register for our free email digests: